Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SHARE PLC. We currently have 8 research reports from 3 professional analysts.
|10Mar17 14:11||RNS||Director/PDMR Shareholding|
|09Mar17 07:00||RNS||Preliminary Results|
|10Feb17 13:23||RNS||Director/PDMR Shareholding|
|13Jan17 12:25||RNS||Director/PDMR Shareholding|
|23Dec16 10:55||RNS||Director/PDMR Shareholding|
|19Dec16 15:55||RNS||Director/PDMR Shareholding|
|19Dec16 11:21||RNS||Realisation of Investment|
Frequency of research reports
Research reports on
Poised for delivery
15 Mar 17
Share plc’s FY16 result was modestly ahead of our expectation and it is making progress in its work to enhance its customer proposition and servicing through significant investment in IT. The results of this should become more evident in the current year and help continue the growth in assets under administration (AUA), potentially helped by further acquisitions of books of accounts and corporate partnerships. As a platform with relatively stable costs once the IT renewal has been completed, increasing scale should feed through to geared profit improvement. Our central valuation of 29p is maintained.
Trading in line and client account acquisition
27 Oct 16
Share indicated that Q3 trading was in line with expectations and it is continuing to implement its IT investment programme to deliver an improved customer experience and greater scalability to provide for future growth. On this front, assets under administration (AUA) have continued to increase organically and an acquisition of a book of accounts has been agreed. This and previously announced partnership agreements with Computershare and a wealth manager are set to begin contributing to revenues next year. Our estimates and valuation are unchanged.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.